Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Dr Reddy's Laboratories Ltd
Revenue
Dr Reddy's Laboratories Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Revenue
₹346.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Revenue
₹283.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Revenue
₹568.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Revenue
₹261.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Revenue
₹127.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Revenue
₹122.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Dr Reddy's Laboratories Ltd
Glance View
In the bustling world of pharmaceuticals, Dr. Reddy's Laboratories Ltd. stands as a testament to innovation and resilience. Founded in 1984 by Dr. K. Anji Reddy, the company embarked on a journey to provide affordable and accessible medicine. Dr. Reddy's merged scientific rigor with a clear vision to eliminate health disparities worldwide. From creating complex generics and active pharmaceutical ingredients (APIs) to providing differentiated formulations, the company has built a strong foundation in both developed markets, like the United States and Europe, as well as in emerging markets such as India, Russia, and the CIS countries. This global footprint ensures that while many pharmaceutical companies are battling regulatory challenges and pricing pressures, Dr. Reddy's stays agile and competitive. The company's revenue streams primarily derive from its diverse portfolio of generic drugs, APIs, branded formulations, biologics, and proprietary products. Each sector is a strategic puzzle piece that enhances its market presence and ensures supply chain efficiency. Dr. Reddy's invests heavily in research and development to bolster its pipeline of future medications, aiming to address unmet medical needs and introduce value-added products. By leveraging strategic alliances and forging partnerships in development and distribution, the company adeptly navigates the complex landscape of the pharmaceutical industry, ensuring sustainable growth and reaffirming its commitment to affordable healthcare globally.
See Also
What is Dr Reddy's Laboratories Ltd's Revenue?
Revenue
346.8B
INR
Based on the financial report for Dec 31, 2025, Dr Reddy's Laboratories Ltd's Revenue amounts to 346.8B INR.
What is Dr Reddy's Laboratories Ltd's Revenue growth rate?
Revenue CAGR 10Y
11%
Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for Dr Reddy's Laboratories Ltd have been 13% over the past three years , 13% over the past five years , and 11% over the past ten years .